Coherus Oncology, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CHRS Nasdaq 2830 www.coherus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coherus Oncology, Inc.

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Jun 25th, 2025 7:55 am
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Jun 6th, 2025 2:29 pm
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics - May 30th, 2025 6:00 am
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - May 27th, 2025 6:30 am
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - May 14th, 2025 5:10 am
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - May 13th, 2025 1:10 am
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2025 3:30 pm
Coherus BioSciences: Q1 Earnings Snapshot - May 12th, 2025 2:27 pm
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - May 12th, 2025 2:15 pm
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 5th, 2025 2:01 pm
Coherus to Participate in Upcoming Investor Conferences - May 1st, 2025 3:04 pm
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - Apr 28th, 2025 8:10 am
Coherus divests Udenyca franchise to Intas for up to $558.4m - Apr 15th, 2025 7:44 am
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - Apr 14th, 2025 6:00 am
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Apr 1st, 2025 6:00 am
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Mar 25th, 2025 2:30 pm
Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position - Mar 24th, 2025 4:30 am
Biotech Alert: Searches spiking for these stocks today - Mar 14th, 2025 10:15 am
Coherus BioSciences Full Year 2024 Earnings: Beats Expectations - Mar 14th, 2025 6:01 am
Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Mar 11th, 2025 1:02 am